European Healthcare Stocks at Valuation Lows as Multiple Institutions Favor Defensive Rotation
Taylor Wilson
Europe's healthcare sector has gained less than 1% this year, far behind the Stoxx 600's 8.3% rally, but UBS, Morningstar, Goldman Sachs, and Deutsche Bank all see headwinds fading and a valuation-repair window approaching.
Why has healthcare lagged so badly?
The Stoxx 600 Healthcare Index is up less than 1% year-to-date, trailing the broader Stoxx Europe 600's 8.3% gain by more than seven percentage points.
Two forces held it down: Trump's return brought renewed drug-pricing pressure and tariff headwinds for firms lacking U.S. manufacturing, while Robert F. Kennedy Jr.'s appointment as health secretary amplified policy uncertainty.
This means → the sector's problem is not broken fundamentals — it is valuation compressed by policy fear, with capital steadily flowing out.
What has changed — why are firms turning bullish now?
UBS strategist Sutanya Chedda argues the investment case is no longer just "defensive quality" — it is now defensive quality + earnings upgrades + low relative valuation + light positioning, four factors stacking together.
Analyst earnings estimates for the sector have begun to turn upward after more than fifteen months of consecutive downgrades, a sharp contrast with the broader market.
Morningstar analysts note that "clarity on drug-pricing pressure is improving, with numerous large pharma companies having reached agreements with the government," and expect insurance rates to better match utilization after 2026.
In plain terms = the bad news that crushed the stocks is being digested, while the good news — an earnings recovery — is only just beginning to be priced in.
Who is being named — which stocks did each firm pick?
UBS favors diversified companies with low patent risk: Merck KGaA and Galderma, plus pipeline-rich large caps AstraZeneca and Roche.
Morningstar flags undervalued opportunities: Sanofi, Genmab, BioMerieux, Elekta, Philips, and Qiagen, which is currently subject to a takeover bid.
Goldman Sachs prefers strong innovation pipelines: Argenx, AstraZeneca, Bayer, GSK, Novartis, and UCB.
This reflects three different stock-picking lenses — UBS on low valuation + low patent exposure, Morningstar on absolute cheapness, Goldman on innovation momentum — but the direction is unanimous: add European healthcare.
What does AI have to do with pharma — where is the long-term variable?
Novo Nordisk partnered with OpenAI and Sanofi with Formation Bio, both using AI agents — software that automates tasks autonomously — to accelerate clinical-trial recruitment and drug development.
Goldman strategist Sharon Bell states: "Long-term pharma profitability depends in large part on whether innovation can offset the impact of patent expirations."
BlackRock CIO Helen Jewell notes the sector currently shows near-zero correlation with the AI trade, but could well become an AI beneficiary in the future.
In plain terms = AI is not yet a stock-price catalyst, but if clinical-trial costs drop sharply thanks to AI, pharma's profit ceiling gets raised.
How cheap is the sector really — what is still missing?
The sector trades below its ten-year average on both absolute and relative forward P/E, at historical lows; relative performance hit a nearly fourteen-year trough in early June before stabilizing.
The dollar provides extra support: roughly 45% of sector revenue comes from North America, making it highly sensitive to USD strength. Deutsche Bank strategists say "valuation, a stronger dollar, and improving earnings together support the sector — we expect healthcare to keep re-rating."
Yet BlackRock's Jewell is candid: "The risk-reward looks attractive, but there is no catalyst, and the market's mood right now is that it needs a catalyst to act."
This means → cheap valuation is the consensus, but a real move still requires defensive rotation to build critical mass in capital flows — one trigger could be enough.
Content is for reference only, not financial advice.